Search tips Search criteria    J Biomol Screen. Author
manuscript; available in PMC 2012 March 22. Published in final
edited form as: PMCID: PMC3310380 Development of a High-
Throughput Screen for Inhibitors of Epstein-Barr Virus EBNA1
Scott Thompson,1 Troy Messick,2 David C. Schultz,1 Melvin
Reichman,3 and Paul M. Lieberman1,4 1The Wistar Institute,
Philadelphia, PA 19104 2Vironika,LLC, Philadelphia, PA 19104
3Lankenau Chemical Genomics, Lankenau Institute for Medical
Research, Wynnewood, PA 4Corresponding Author Paul M. Lieberman
3601 Spruce Street Philadelphia, PA 19104 ; Lieberman/at/ Phone:
215-898-9491 Fax: 215-898-0663 Latent infection with Epstein-
Barr Virus (EBV) is a carcinogenic cofactor in several lymphoid
and epithelial cell malignancies. At present, there are no small
molecule inhibitors that specifically target EBV latent
infection or latency-associated oncoproteins. EBNA1 is an EBV-
encoded sequence-specific DNA-binding protein that is
consistently expressed in EBV-associated tumors and required